COMPARE · Reviewed August 10, 2026
HALO vs OSCR
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 85.5, OSCR scored 88.4 — OSCR leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
85.5
$102.62 · $12.2B
fundamentals as of
Score gap
2.9
OSCR leads
OSCR
Oscar Health, Inc.
88.4
$27.67 · $8.5B
fundamentals as of
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
OSCR
96
Qualityreturns · margins · balance sheet
79
100
Growthrevenue & earnings expansion
100
65
Valuevaluation vs sector peers
88
HALO and OSCR split the three pillars evenly.
Fundamentals, head-to-head
HALO
OSCR
$806mC+
FCF
$4.4bB
+41.2%A
Rev
+27.5%A-
—
D/E
0.23B
30.1xB
P/E
21.3xB+
0.80A-
PEG
0.77A-
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
OSCR
39% below
Price vs fair valuelower is cheaper
78% below
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
decline
+30%
1-yr DCF upside
+344%
+64%
5-yr DCF upside
+349%
+131%
10-yr DCF upside
+356%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
OSCR
No notable signals flagged.
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.2b. Trading near 52-week high of $104.73 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. PEG 0.80 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $97.33 (implying -5% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 30x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
OSCROscar Health, Inc.
Why now
Healthcare Plans · market cap $8.5b. 16% off the 52-week high of $33.10. Revenue growing +27% — in hypergrowth territory. PEG 0.77 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Hold with a mean 1-yr target of $28.20 (implying +2% upside).
Moat
ROE 34% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong.
Risk
Beta 2.38 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Net margin 3.6% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HALO and OSCR diverge
On the headline score the gap is 2.9 points in favour of OSCR. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueHALO 65.4 · OSCR 87.7OSCR +22.3
- QualityHALO 95.7 · OSCR 78.9HALO +16.8
- GrowthHALO 100.0 · OSCR 100.0level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.